mOPV

PreclinicalBiologic

AAga Khan University

mOPV is one of 5 biologic programs targeting Immunization. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ImmunizationUnknown status

ImmunizationPreclinical

Unknown status

Competition

Competitive Landscape

6 competitors in Immunization

#DrugCompanyPhaseTrials

ABRYSVO

Pfizer

Phase 3

1 2

HPV Vaccine

SShanghai Zerun Biotechnology Co.,Ltd

Phase 2

1 3

Measles

GSK

Phase 2

1 4

mOPV

AAga Khan University

Preclinical

1 5

Fractional IPV

CCenters for Disease Control and Prevention

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunization1 trial

Use of mOPV1 in Routine Immunization in Pakistan.

Unknown status·—·N/A·NCT04504539·560 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for mOPV. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — mOPV compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for mOPV. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aga Khan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: AAga Khan University

mOPV

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Immunization1 trial

References

Drug Info

Quick Facts

Related News